NEOGEN CORP (NEOG) Stock Fundamental Analysis
NASDAQ:NEOG - US6404911066 - Common Stock
5.73 USD
+0.07 (+1.15%)
5.8199 USD
+0.09 (+1.57%)
Taking everything into account, NEOG scores 3 out of 10 in our fundamental rating. NEOG was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of NEOG is average, but there are quite some concerns on its profitability. NEOG has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NEOG had positive earnings in the past year.
In the past year NEOG had a positive cash flow from operations.
In multiple years NEOG reported negative net income over the last 5 years.
Each year in the past 5 years NEOG had a positive operating cash flow.
1.2 Ratios
NEOG has a Return On Assets (-31.71%) which is comparable to the rest of the industry.
The Return On Equity of NEOG (-52.72%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.71% | ||
| ROE | -52.72% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 47.10%, NEOG is in line with its industry, outperforming 40.53% of the companies in the same industry.
NEOG's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEOG has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, NEOG has more shares outstanding
The debt/assets ratio for NEOG is higher compared to a year ago.
2.2 Solvency
NEOG has an Altman-Z score of 0.72. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.72, NEOG is in line with its industry, outperforming 50.53% of the companies in the same industry.
NEOG has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NEOG (0.42) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.72 |
ROIC/WACCN/A
WACC7.58%
2.3 Liquidity
A Current Ratio of 3.32 indicates that NEOG has no problem at all paying its short term obligations.
NEOG has a better Current ratio (3.32) than 62.63% of its industry peers.
A Quick Ratio of 2.22 indicates that NEOG has no problem at all paying its short term obligations.
NEOG has a Quick ratio (2.22) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.22 |
3. Growth
3.1 Past
The earnings per share for NEOG have decreased strongly by -25.00% in the last year.
Measured over the past years, NEOG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.20% on average per year.
NEOG shows a decrease in Revenue. In the last year, the revenue decreased by -3.20%.
Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-50%
Revenue 1Y (TTM)-3.2%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-4.79%
3.2 Future
Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 0.40% on average per year.
Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y-24.27%
EPS Next 2Y3.26%
EPS Next 3Y-1.41%
EPS Next 5Y0.4%
Revenue Next Year-7.92%
Revenue Next 2Y-3.15%
Revenue Next 3Y-1.21%
Revenue Next 5Y0.6%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.36, the valuation of NEOG can be described as rather expensive.
Based on the Price/Earnings ratio, NEOG is valued cheaper than 81.58% of the companies in the same industry.
NEOG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 22.93 indicates a rather expensive valuation of NEOG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 76.84% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.59, NEOG is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.36 | ||
| Fwd PE | 22.93 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 78.42% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.21 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.26%
EPS Next 3Y-1.41%
5. Dividend
5.1 Amount
NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.73
+0.07 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners117.15%
Inst Owner Change-5%
Ins Owners0.2%
Ins Owner Change84.69%
Market Cap1.24B
Analysts78
Price Target6.63 (15.71%)
Short Float %7.96%
Short Ratio2.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.76%
Min EPS beat(2)-34.64%
Max EPS beat(2)-10.87%
EPS beat(4)1
Avg EPS beat(4)-13.3%
Min EPS beat(4)-34.64%
Max EPS beat(4)11.56%
EPS beat(8)1
Avg EPS beat(8)-15.08%
EPS beat(12)3
Avg EPS beat(12)39.16%
EPS beat(16)4
Avg EPS beat(16)23.61%
Revenue beat(2)0
Avg Revenue beat(2)-2.03%
Min Revenue beat(2)-3.66%
Max Revenue beat(2)-0.4%
Revenue beat(4)0
Avg Revenue beat(4)-1.34%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)-0.19%
Revenue beat(8)1
Avg Revenue beat(8)-1.4%
Revenue beat(12)2
Avg Revenue beat(12)-1.25%
Revenue beat(16)3
Avg Revenue beat(16)-1%
PT rev (1m)0%
PT rev (3m)-23.53%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)-61.29%
EPS NY rev (1m)-31.94%
EPS NY rev (3m)-38.75%
Revenue NQ rev (1m)-0.96%
Revenue NQ rev (3m)-8.55%
Revenue NY rev (1m)-0.41%
Revenue NY rev (3m)-8.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.36 | ||
| Fwd PE | 22.93 | ||
| P/S | 1.39 | ||
| P/FCF | N/A | ||
| P/OCF | 21.37 | ||
| P/B | 0.6 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.21 |
EPS(TTM)0.33
EY5.76%
EPS(NY)0.25
Fwd EY4.36%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)0.27
OCFY4.68%
SpS4.12
BVpS9.54
TBVpS-1.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.71% | ||
| ROE | -52.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.1% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.06 | ||
| Cap/Depr | 83.23% | ||
| Cap/Sales | 11.69% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 46.97% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.22 | ||
| Altman-Z | 0.72 |
F-Score3
WACC7.58%
ROIC/WACCN/A
Cap/Depr(3y)83.18%
Cap/Depr(5y)95.92%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-50%
EPS Next Y-24.27%
EPS Next 2Y3.26%
EPS Next 3Y-1.41%
EPS Next 5Y0.4%
Revenue 1Y (TTM)-3.2%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-4.79%
Revenue Next Year-7.92%
Revenue Next 2Y-3.15%
Revenue Next 3Y-1.21%
Revenue Next 5Y0.6%
EBIT growth 1Y-102.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year137.27%
EBIT Next 3Y34.41%
EBIT Next 5Y19.96%
FCF growth 1Y39.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.17%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%